

## **LIFECARE SHARES KEY LEARNINGS FROM ONGOING LONGEVITY STUDY LFC-SEN-002**

**Bergen, Norway, 5 November 2025 – Lifecare ASA (LIFE), a MedTech company developing next-generation implantable Continuous Glucose Monitoring (CGM) technology, today shares key learnings from the ongoing *LFC-SEN-002 longevity study*.**

Our pilot results to date confirm biocompatibility and provide valuable insight guiding the next generation of Lifecare's implantable continuous glucose monitor.

The purpose of the study is to evaluate long-term performance, biocompatibility, and usability of Lifecare's implant, as well as key product features in live settings. The overall study includes both laboratory evaluations and live testing with dogs, supporting both the upcoming veterinary market entry and the company's CE-mark pathway for human use.

The pilot testing in dogs, based on authorization by the Norwegian Food Safety Authority (*Mattilsynet*), has been conducted under veterinary supervision at the Faculty of Veterinary Medicine, Department of Companion Animal Clinical Sciences at the Norwegian University of Life Sciences (NMBU). The live testing in dogs has provided substantial insights that directly inform the ongoing development program.

- **Biocompatibility and safety confirmed:**

The implants were well tolerated, with biopsies and pathology analyses showing normal tissue response and no signs of adverse reactions.

- **Functional data collection achieved:**

Signals consistent with changes in interstitial glucose levels successfully transmitted from the subcutaneous sensor via the Lifecare collar and app, confirming end-to-end system performance.

- **Identified improvement areas:**

The test highlighted specific technical refinements now implemented in the new generation of implants, including:

- Improved signal-to-noise ratio using a piezoelectric sensing element;
- Enhanced encapsulation integrity with verified material stability;
- Optimized antenna design and collar connectivity, including testing of a harness configuration for stable signal transmission;
- Firmware updates for data storage and battery management.

The longevity study is still ongoing in close collaboration with NMBU. In October, the Norwegian Food Safety Authority issued a new authorization for continued testing in dogs, explicitly a prolongation. On this basis the tests will be expanded to also include diabetic dogs.

Insights from LFC-SEN-002 directly support Lifecare's parallel regulatory and product development workstreams:

- Preparation for veterinary market launch in 2026;
- Preparation for first-in-human clinical trial in 2026;
- Integration of findings into Lifecare's ISO 13485 documentation for CE marking.

#### **About LFC-SEN-002**

The LFC-SEN-002 study is conducted by Lifecare in collaboration with Department of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine at the Norwegian University of Life Sciences. The project investigates sensor longevity, biocompatibility, and accuracy in dogs, as well as key product features in live settings, with the goal of supporting regulatory and clinical documentation for future veterinary and human CGM products.

#### **About us**

Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("**CGM**") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

#### **Contacts**

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42